Atavistik Bio gathers $60m Series A

Atavistik Bio, a pre-clinical biotechnology company, has raised $60 million in Series A financing.

Atavistik Bio, a pre-clinical biotechnology company, has raised $60 million in Series A financing. The Column Group led the round with participation from Lux Capital and Nextech Invest Ltd.

Source: Press Release